{'fraction_non_alphanumeric': 0.030425963488843813, 'fraction_numerical': 0.013184584178498986, 'mean_word_length': 5.16875, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Brugada syndrome: Screening protocols in high-risk populations

OBJECTIVE Brugada syndrome is a cardiac disorder, typically asymptomatic, characterized by ECG abnormalities and an increased risk for sudden cardiac death (SCD). The prevalence of Brugada syndrome is about 0.05% in the United States but is much higher among Southeast Asians (0.5%), and Filipinos (2.1%). Brugada syndrome has an 8:1 maleto-female predominance and the average age of death is 40 years. Up to 20% of all SCDs that occur in patients without underlying cardiac structural abnormality are due to Brugada syndrome. ECG screening is highly sensitive in determining the risk for lethal dysrhythmias due to Brugada syndrome. To prevent SCD, early detection of the disorder is paramount, as an implantable cardioverter defi brillator is the only effective treatment. This study sought to determine whether the current primary care screening methods are likely to identify Brugada syndrome in high-risk populations.